1. Smolen J, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007:1861-74. 
  2. Rheumatology Expert Group. Therapeutic Guidelines: Rheumatology. West Melbourne: Therapeutic Guidelines Ltd, 2017 (accessed 2 November 2017).
  3. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77. 
  4. Wilsdon TD, Hill CL. Managing the drug treatment of rheumatoid arthritis. Aust Prescr 2017;40:51-8. 
  5. van der Linden M, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis,. Arthritis Rheum 2010;62. 
  6. Arnold M, Bleasel J, Haq I. Nocebo effects in practice: methotrexate myths and misconceptions Med J Aust 2016;205:440-2. 
  7. Schulman E, Bartlett SJ, Schieir O, et al. Overweight and obesity reduce the likelihood of achieving sustained remission in early rheumatoid arthritis: Results from the Canadian Early Arthritis Cohort Study. Arthritis Care Res (Hoboken) 2017. 
  8. eTG complete. Therapeutic guidelines: Drug use in pregnancy and breastfeeding 2017 (accessed 21 December 2017).